Systematic review and meta-analysis of reported adverse events of long-term intranasal oxytocin treatment for autism spectrum disorder
Psychiatry and Clinical Neurosciences | Dec 17, 2017
Cai Q, et al. - This systematic review was designed to identify the side effect profile of long-term intranasal oxytocin in the treatment of autism spectrum disorder (ASD) compared to placebo. In ASD population, intranasal oxytocin use was found to be well tolerated and safe.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
